Drug Profile
Ad-GMCAIX transduced dendritic cells - Kite Pharma
Alternative Names: DC AdGM CAIXLatest Information Update: 13 Aug 2021
Price :
$50
*
At a glance
- Originator University of California at Los Angeles
- Developer National Cancer Institute (USA); UCLAs Jonsson Comprehensive Cancer Center
- Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Renal cell carcinoma
Most Recent Events
- 27 May 2021 Jonsson Comprehensive Cancer Center and Kite Pharma completes a phase I trial in Renal cell carcinoma in USA (NCT01826877)
- 28 Jun 2020 No recent reports of development identified for phase-I development in Renal-cell-carcinoma in USA (Intradermal, Injection)
- 07 Jun 2018 Phase I development is ongoing in USA (NCT01826877)